Allergies News and Research

Latest Allergies News and Research

Advanced Liquid Logic awarded an NIAID contract to develop a rapid HIV diagnostic device

Advanced Liquid Logic awarded an NIAID contract to develop a rapid HIV diagnostic device

Fovea Pharmaceuticals to sell 100% of its share to Sanofi-Aventis

Fovea Pharmaceuticals to sell 100% of its share to Sanofi-Aventis

MSN launches new online service to help people manage healthcare decisions

MSN launches new online service to help people manage healthcare decisions

Annual campaign to help patients learn about, manage and prevent diabetes

Annual campaign to help patients learn about, manage and prevent diabetes

Biology and geography scientists explain the spread of HIV-1 epidemic in Africa

Biology and geography scientists explain the spread of HIV-1 epidemic in Africa

Emergent BioSolutions receives NIAID funding support for dmPA7909 anthrax vaccine candidate

Emergent BioSolutions receives NIAID funding support for dmPA7909 anthrax vaccine candidate

FDA approves Mylan Pharmaceuticals' Carbidopa and Levodopa tablets

FDA approves Mylan Pharmaceuticals' Carbidopa and Levodopa tablets

IDRI and Academia Sinica sign Memorandum of Understanding

IDRI and Academia Sinica sign Memorandum of Understanding

Hookworms can prevent asthma

Hookworms can prevent asthma

Medical experts explore future of health advancements at Military Medicine Symposium

Medical experts explore future of health advancements at Military Medicine Symposium

Heparin-induced skin lesions may indicate platelets deficit

Heparin-induced skin lesions may indicate platelets deficit

Combined immunodeficiency results in severe health problems

Combined immunodeficiency results in severe health problems

U.S. underfunds climate change health-related research

U.S. underfunds climate change health-related research

Child health experts to gather in Italy for Excellence in Paediatrics conference

Child health experts to gather in Italy for Excellence in Paediatrics conference

Investigational vaccine regimen 31% effective in preventing HIV infection

Investigational vaccine regimen 31% effective in preventing HIV infection

GenVec to receive $2.3M from NIAID for HIV vaccine candidate production

GenVec to receive $2.3M from NIAID for HIV vaccine candidate production

Virginia Tech student granted fellowship for research study on LaCrosse Virus disease

Virginia Tech student granted fellowship for research study on LaCrosse Virus disease

Neogen announces first-quarter results of fiscal 2010

Neogen announces first-quarter results of fiscal 2010

Phase III clinical trial of investigational HIV vaccine regimen complete

Phase III clinical trial of investigational HIV vaccine regimen complete

Investigational vaccine shows modest potential for protecting against HIV infection

Investigational vaccine shows modest potential for protecting against HIV infection

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.